155 related articles for article (PubMed ID: 20584580)
1. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer.
Scheer RV; Fakiris AJ; Johnstone PA
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):996-1001. PubMed ID: 20584580
[TBL] [Abstract][Full Text] [Related]
2. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
[TBL] [Abstract][Full Text] [Related]
3. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy?
Fogh SE; Yu A; Kubicek GJ; Scott W; Mitchell E; Rosato EL; Berger AC
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1372-6. PubMed ID: 21106309
[TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
5. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.
Kim MP; Correa AM; Lee J; Rice DC; Roth JA; Mehran RJ; Walsh GL; Ajani JA; Maru DM; Chang JY; Marom EM; Macapinlac HA; Lee JH; Vaporciyan AA; Rice T; Swisher SG; Hofstetter WL
Ann Thorac Surg; 2010 Sep; 90(3):884-90; discussion 890-1. PubMed ID: 20732513
[TBL] [Abstract][Full Text] [Related]
6. [New trends in neoadjuvant chemoradiotherapy for locally-advanced esophageal cancer: esophagectomy--is it necessary?].
Fujita H; Sueyoshi S; Tanaka T; Toh U; Mine T; Sasahara H; Shirouzu K; Yamana H; Toda Y; Hayabuchi N
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2016-22. PubMed ID: 11103231
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns.
Koshy M; Greenwald BD; Hausner P; Krasna MJ; Horiba N; Battafarano RJ; Burrows W; Suntharalingam M
Am J Clin Oncol; 2011 Jun; 34(3):259-64. PubMed ID: 20686405
[TBL] [Abstract][Full Text] [Related]
8. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
[TBL] [Abstract][Full Text] [Related]
10. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study.
Schwer AL; Ballonoff A; McCammon R; Rusthoven K; D'Agostino RB; Schefter TE
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):449-55. PubMed ID: 18538500
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas.
Kato H; Fukuchi M; Manda R; Faried A; Takita J; Nakajima M; Miyazaki T; Sohda M; Fukai Y; Masuda N; Tsukada K; Kuwano H
Anticancer Res; 2004; 24(6):4091-6. PubMed ID: 15736457
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.
Malaisrie SC; Untch B; Aranha GV; Mohideen N; Hantel A; Pickleman J
Arch Surg; 2004 May; 139(5):532-8; discussion 538-9. PubMed ID: 15136354
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
[TBL] [Abstract][Full Text] [Related]
15. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
Henry LR; Goldberg M; Scott W; Konski A; Meropol NJ; Freedman G; Weiner LM; Watts P; Beard M; McLaughlin S; Cheng JD
Ann Surg Oncol; 2006 Feb; 13(2):214-20. PubMed ID: 16418887
[TBL] [Abstract][Full Text] [Related]
16. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer.
Nakamura T; Hayashi K; Ota M; Eguchi R; Ide H; Takasaki K; Mitsuhashi N
Am J Surg; 2004 Sep; 188(3):261-6. PubMed ID: 15450831
[TBL] [Abstract][Full Text] [Related]
17. Esophageal cancer: outcomes of surgery, neoadjuvant chemotherapy, and three-dimension conformal radiotherapy.
Fréchette E; Buck DA; Kaplan BJ; Chung TD; Shaw JE; Kachnic LA; Neifeld JP
J Surg Oncol; 2004 Aug; 87(2):68-74. PubMed ID: 15282698
[TBL] [Abstract][Full Text] [Related]
18. Preoperative therapy for esophageal cancer.
Ku GY; Ilson DH
Gastroenterol Clin North Am; 2009 Mar; 38(1):135-52, ix. PubMed ID: 19327572
[TBL] [Abstract][Full Text] [Related]
19. [Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy].
Takemura M; Osugi H; Lee S; Nishikawa T; Fukuhara K; Iwasaki H
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1023-7. PubMed ID: 16044966
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
